• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SeqLL Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    11/16/23 4:57:50 PM ET
    $SQL
    Medical Specialities
    Health Care
    Get the next $SQL alert in real time by email
    0001605888 false 0001605888 2023-11-10 2023-11-10 0001605888 SEQL:CommonStockParValue.00001PerShareMember 2023-11-10 2023-11-10 0001605888 SEQL:WarrantsToPurchaseCommonStockMember 2023-11-10 2023-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) November 10, 2023

     

    SEQLL INC.

    (Exact name of registrant as specified in charter)

     

    Delaware   001-40760   46-5319744
    (State or other Jurisdiction of
    Incorporation or Organization)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    3 Federal Street
    Billerica, Massachusetts
      01821
    (Address of Principal Executive Offices)   (zip code)

     

    (781) 460-6016

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.00001 per share   SQL   The Nasdaq Stock Market LLC
    Warrants to purchase Common Stock   SQLLW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously reported, on September 8, 2023, SeqLL Inc. (the “Company”) received a letter from the Listing Qualifications Staff ( the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”), which requires the Company to have a minimum of 500,000 publicly held shares, exclusive of shares held by officers, directors and 10% stockholders. The letter from Nasdaq indicated that according to its calculations, as of September 7, 2023, the Company no longer met the requirements of the Rule. On September 18, 2023, the Company received a letter from the Listing Qualifications Staff of Nasdaq that supplemented the letter of September 8, 2023 and requested that the Company submit to the Nasdaq Hearings Panel (the “Panel”) a letter with its plan to regain compliance with the Rule by September 25, 2023.

     

    On September 18, 2023, the Staff issued an additional delist determination letter for the Company’s failure to maintain compliance with the Rule and on October 17, 2023, the Staff advised the Company that the Panel had issued a final extension and advised the Company that its failure to meet the Rule by October 31, 2023 would result in the Company’s immediate delisting from the Nasdaq exchange.

     

    On November 10, 2023, the Company received a letter from Nasdaq advising the Company that in light of the Company’s inability to meet the terms of the Panel’s amended decision of October 17, 2023, the Panel had determined to delist the Company’s securities from Nasdaq and suspend trading in those securities effective at the open of trading on November 13, 2023. The letter further advised that Nasdaq will complete the delisting by filing a Form 25 Notice of Delisting with the Securities and Exchange Commission, after applicable appeal periods have lapsed. The Company has appealed the decision of the Panel and paid the applicable filing fee for such appeal; however no date has been set for the hearing of such appeal.

     

    As previously disclosed, in connection with the transactions contemplated by the Agreement and Plan of Reorganization dated as of May 29, 2023, as amended (the “Merger Agreement”), among the Company, SeqLL Merger LLC, Atlantic Acquisition Corp., Atlantic Merger LLC, Lyneer Investments, LLC, IDC Technologies, Inc. and Lyneer Management Holdings LLC, the Company has filed a registration statement on Form S-1 for the sale of its securities in connection with the closing of the transactions contemplated by the Merger Agreement. As previously reported, the Company had intended to cure its Nasdaq listing deficiency by consummating the transactions contemplated by the Merger Agreement and the proposed public offering by October 31, 2023. The Company has advised Nasdaq that it intends to proceed with such transactions and the proposed public offering of its securities and that it intends to relist its securities on Nasdaq in connection with the closing of such transactions and such public offering.

     

    Forward-Looking Statements

     

    This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words like “believe,” “intend,” “will,” and “would” or the negative thereof or other variations thereon or comparable terminology, are used to identify forward-looking statements, although not all forward-looking statements contain these words. Although the Company believes that it is basing its expectations and beliefs on reasonable assumptions within the bounds of what is currently known about its business and operations, there can be no assurance that actual results will not differ materially from what the Company expects or believes. Some of the factors that could cause the Company’s actual results to differ materially from its expectations or beliefs are disclosed in the “Risk Factors” section, as well as other sections, of its reports and registration statements filed with the Securities and Exchange Commission, which include, without limitation, its ability to obtain and maintain the listing of its securities on Nasdaq, and its ability to complete a public offering of its securities. All forward-looking statements speak only as of the date on which they are made and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    No Offer or Solicitation

     

    This report does not constitute an offer to sell or the solicitation of an offer to buy any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933 as amended (the “Securities Act”), or an exemption from the registration requirements of the Securities Act.

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 16, 2023 SEQLL INC.
         
      By: /s/ Daniel Jones
      Name:  Daniel Jones
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $SQL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQL

    DatePrice TargetRatingAnalyst
    2/9/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $SQL
    SEC Filings

    See more
    • SEC Form EFFECT filed by SeqLL Inc.

      EFFECT - SeqLL, Inc. (0001605888) (Filer)

      2/13/24 12:15:19 AM ET
      $SQL
      Medical Specialities
      Health Care
    • SEC Form S-1/A filed by SeqLL Inc. (Amendment)

      S-1/A - SeqLL, Inc. (0001605888) (Filer)

      2/12/24 3:01:45 PM ET
      $SQL
      Medical Specialities
      Health Care
    • SEC Form S-1/A filed by SeqLL Inc. (Amendment)

      S-1/A - SeqLL, Inc. (0001605888) (Filer)

      2/9/24 5:23:38 PM ET
      $SQL
      Medical Specialities
      Health Care

    $SQL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Pfeffer David bought $20,163 worth of shares (20,000 units at $1.01), increasing direct ownership by 22% to 20,000 units (Amendment)

      4/A - SeqLL, Inc. (0001605888) (Issuer)

      1/30/23 11:37:35 AM ET
      $SQL
      Medical Specialities
      Health Care
    • SEC Form 4: Milos Patrice M. bought $10,088 worth of shares (10,000 units at $1.01), increasing direct ownership by 14% to 10,000 units (Amendment)

      4/A - SeqLL, Inc. (0001605888) (Issuer)

      1/30/23 11:37:03 AM ET
      $SQL
      Medical Specialities
      Health Care
    • SEC Form 4: Jones Daniel Robert bought $2,236 worth of shares (5,733 units at $0.39), increasing direct ownership by 0.24% to 2,392,365 units (Amendment)

      4/A - SeqLL, Inc. (0001605888) (Issuer)

      1/30/23 11:36:38 AM ET
      $SQL
      Medical Specialities
      Health Care

    $SQL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atlantic International Corp. Acquires Lyneer Staffing Solutions

      ENGLEWOOD CLIFFS, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- Atlantic International Corp. (OTC:ATLN) (OTC:SEQL) today announced the acquisition ("Acquisition") of Lyneer Staffing Solutions ("Lyneer"), a 28 year old national strategic staffing outsourced services and workforce solutions company servicing the commercial, professional, finance, direct placement, and managed service provider verticals. Lyneer has over 1,100 customers, including, among others, enterprise scale customers UPS, DHL, FedEx, XPO Logistics, Ryder, Ikea, PepsiCo, T-Mobile, Kraft Heinz, and Red Bull. The Company is using its best efforts to uplist in the near future onto a National Securities Exchange and remains optimist

      6/21/24 7:00:00 AM ET
      $SQL
      Medical Specialities
      Health Care
    • SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition

      BILLERICA, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ:SQL, SQLLW))), today announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC ("Lyneer") and the disposition of its current business operations. The Company had previously set September 26, 2023 as the record date for the dividends (the "Record Date"). While the Record Date had been set, the dividends had not yet been declared by the Board nor had the amount of the proposed dividends been set

      10/30/23 4:30:00 PM ET
      $SQL
      Medical Specialities
      Health Care
    • SeqLL Announces Cash and Stock Dividend Record Date

      BILLERICA, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ:SQL, SQLLW))), announced today that its board of directors has set September 26, 2023 as the record date for its special stock dividend and cash dividend to be made to the holders of its common stock pursuant to the terms of the Agreement and Plan of Reorganization dated as of May 29, 2023, as amended (the "Merger Agreement"), by and among the Company, SeqLL Merger LLC, Atlantic Acquisition Corp., Atlantic Merger LLC, Lyneer Investments, LLC, IDC Technologies, Inc. and Lyneer Management Holdings LLC. The dividend distribution of shares of common stock of the Company and the cash dividend will

      9/15/23 5:24:58 PM ET
      $SQL
      Medical Specialities
      Health Care

    $SQL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on SeqLL with a new price target

      Maxim Group initiated coverage of SeqLL with a rating of Buy and set a new price target of $3.00

      2/9/22 8:40:22 AM ET
      $SQL
      Medical Specialities
      Health Care

    $SQL
    Financials

    Live finance-specific insights

    See more
    • Atlantic International Corp. Acquires Lyneer Staffing Solutions

      ENGLEWOOD CLIFFS, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- Atlantic International Corp. (OTC:ATLN) (OTC:SEQL) today announced the acquisition ("Acquisition") of Lyneer Staffing Solutions ("Lyneer"), a 28 year old national strategic staffing outsourced services and workforce solutions company servicing the commercial, professional, finance, direct placement, and managed service provider verticals. Lyneer has over 1,100 customers, including, among others, enterprise scale customers UPS, DHL, FedEx, XPO Logistics, Ryder, Ikea, PepsiCo, T-Mobile, Kraft Heinz, and Red Bull. The Company is using its best efforts to uplist in the near future onto a National Securities Exchange and remains optimist

      6/21/24 7:00:00 AM ET
      $SQL
      Medical Specialities
      Health Care
    • SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition

      BILLERICA, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ:SQL, SQLLW))), today announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC ("Lyneer") and the disposition of its current business operations. The Company had previously set September 26, 2023 as the record date for the dividends (the "Record Date"). While the Record Date had been set, the dividends had not yet been declared by the Board nor had the amount of the proposed dividends been set

      10/30/23 4:30:00 PM ET
      $SQL
      Medical Specialities
      Health Care
    • SeqLL Inc. Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition Corp.

      BILLERICA, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ:SQL, SQLLW))), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Lyneer Investments, LLC ("Lyneer"), the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp. ("Atlantic"), and related parties, pursuant to which Lyneer will become a wholly-owned subsidiary of SeqLL. Under the terms of the Merger Agreement, SeqLL will pay $60,000,000 in cash to the Lyneer members, and issue to the Lyneer members and Atlantic, an aggregate o

      5/30/23 8:30:00 AM ET
      $SQL
      Medical Specialities
      Health Care